Latest Breaking News On - Chromium controller - Page 1 : vimarsana.com

10x Genomics, Inc Share Price Target $58 50 , now 21 7% Upside Potential

10x Genomics, Inc. Share Price Target '$58.50', now 21.7% Upside Potential

Genomics incChromiumx seriesChromium connectChromium controllerChromium single cell gene expressionChromium single cell gene expression flexChromium single cell immune profilingChromium single cellChromium single cell multiomeGene expressionVisium spatial gene expressionVisium spatial proteogenomicsXenium in situ gene

10x Genomics, Inc - Consensus buy rating and 21 0% Upside Potential

10x Genomics, Inc. - Consensus 'buy' rating and 21.0% Upside Potential

Paylocity holding corporationGenomics incChromiumx seriesChromium connectChromium controllerChromium single cell gene expressionChromium single cell gene expression flexChromium single cell immune profilingChromium single cellChromium single cell multiomeGene expressionVisium spatial gene expressionVisium spatial proteogenomicsXenium in situ gene

MedGenome achieves 10x Genomics Certified Service provider qualification for single cell sequencing

MedGenome achieves 10x Genomics Certified Service provider qualification for single cell sequencing
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Foster cityUnited statesSan francisco bayPrnewswire medgenomeGenomics certified service providerResearch servicesNovo holdingsFrancisco bayChromium controller

10x Genomics, Inc - Consensus buy rating and 71 0% Upside Potential

10x Genomics, Inc. - Consensus 'buy' rating and 71.0% Upside Potential

Genomics incChromiumx seriesChromium connectChromium controllerChromium single cell gene expressionChromium single cell gene expression flexChromium single cell immune profilingChromium single cellChromium single cell multiomeGene expressionVisium spatial gene expressionVisium spatial proteogenomicsXenium in situ gene

10x Genomics, Inc - Consensus buy rating and 12 7% Upside Potential

10x Genomics, Inc. - Consensus 'buy' rating and 12.7% Upside Potential

Genomics incPaylocity holding corporationChromiumx seriesChromium connectChromium controllerChromium single cell gene expressionChromium single cell gene expression flexChromium single cell immune profilingChromium single cellChromium single cell multiomeGene expressionVisium spatial gene expressionVisium spatial proteogenomicsXenium in situ gene